| Trial ID: | L3100 |
| Source ID: | NCT02050074
|
| Associated Drug: |
Colesevelam
|
| Title: |
The Role of Metformin and Colesevelam in Human GLP-1 Secretion
|
| Acronym: |
ColMetInc
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Colesevelam|DRUG: Metformin|OTHER: Placebo
|
| Outcome Measures: |
Primary: Change in the gut hormone glucagon-like peptide 1 (GLP-1), 0-240 min |
|
| Sponsor/Collaborators: |
Sponsor: University Hospital, Gentofte, Copenhagen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2014-01
|
| Completion Date: |
2014-09
|
| Results First Posted: |
|
| Last Update Posted: |
2014-10-07
|
| Locations: |
Diabetes Research Division, Department of Medicine, Gentofte Hospital, Hellerup, Copenhagen, 2900, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT02050074
|
